Acarix AB (”Acarix” or the "Company") has, as previously announced, completed the rights issue of
shares amounting to approximately SEK 56 million, which was announced on 15 July 2020 and
approved by the extraordinary general meeting on 11 August 2020 (the ”Rights Issue”). In
connection herewith, in accordance with the guarantee undertakings that have been entered into,
a directed issue of shares is carried out to the guarantors in the Rights Issue who have chosen to
receive guarantee commission in the form of newly issued shares in the Company (the
“Compensation Issue"). The subscription price in the Compensation Issue is set at SEK 0.712 per
share and payment is made through set-off of the guarantors' claims.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, firstname.lastname@example.org) is Certified Advisor of Acarix.